Share ownership Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 16:35:28 15/05/2026 BST			5-day change	1st Jan Change
18.88 ^EUR	-0.63%		+0.43%	-26.25%

04-24	Deutsche Börse News: 'Corporate bonds move into focus'	DP
04-22	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Share class: Formycon AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,672,927	12,371,049 ( 70 %)	0	70 %

Major shareholders: Formycon AG

Name	Equities	%	Valuation
Struengmann Family 24.03 %	4,246,528	24.03 %	90 M €
Wendeln & Cie. KG 13.24 %	2,340,537	13.24 %	50 M €
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. 9.075 %	1,603,877	9.075 %	34 M €
Active Ownership Corp SARL 6.037 %	1,066,931	6.037 %	23 M €
Detlef Spruth 5.094 %	900,206	5.094 %	19 M €
Stefan Reichensperger 3.277 %	579,133	3.277 %	12 M €
Paladin Asset Management Investmentaktiengesellschaft TGV 0.2483 %	43,876	0.2483 %	931 584 €
GS&P Kapitalanlagegesellschaft SA 0.1839 %	32,500	0.1839 %	690 047 €
Proaktiva GmbH 0.0905 %	16,000	0.0905 %	339 715 €
Aktia Varainhoito Oy 0.0824 %	14,555	0.0824 %	309 035 €
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	32.4%
Other	22.32%
Institutional	6.96%
Unknown	38.32%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	32.4%
Germany	13.78%
Hungary	9.08%
Luxembourg	6.28%
Finland	0.14%
Ireland	0.01%

Based on 1000 largest holdings

Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.

Employees

250

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q1 2026

More about the company